Literature DB >> 9353695

Modeling of trough plasma bismuth concentrations.

J E Bennett1, J C Wakefield, L F Lacey.   

Abstract

Disposition pharmacokinetics of bismuth following oral dosing of ranitidine bismuth citrate are complicated and variable. An analysis of data from healthy volunteers suggests a model with three disposition compartments and first-order absorption. Patient data are pooled from 10 separate studies and consist of 1140 trough concentrations measured in 802 patients following dosing of 2 to 12 weeks duration. There are therefore insufficient data to obtain reliable parameter estimates for the full model and we use instead a much reduced model and an informative prior based on the volunteer data. Individual parameter estimates from this model can then be used to establish covariate relationships. Trough concentrations were influenced by the coadministration of clarithromycin and by creatinine clearance. A simulation study was carried out to check the validity of the estimates obtained from the reduced model. We carry out analysis via Bayesian sampling-based techniques. Throughout, we use predictive distributions for both diagnostic and inference purposes. In particular, we determine predicted distributions for the Cmax, Cmin and AUC characteristics of new individuals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9353695     DOI: 10.1023/a:1025771811143

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  9 in total

Review 1.  Safety and pharmacokinetics: colloidal bismuth subcitrate.

Authors:  L Z Benet
Journal:  Scand J Gastroenterol Suppl       Date:  1991

2.  Bayesian individualization via sampling-based methods.

Authors:  J Wakefield
Journal:  J Pharmacokinet Biopharm       Date:  1996-02

3.  Estimation of population pharmacokinetics using the Gibbs sampler.

Authors:  N G Best; K K Tan; W R Gilks; D J Spiegelhalter
Journal:  J Pharmacokinet Biopharm       Date:  1995-08

4.  A comparison of a Bayesian population method with two methods as implemented in commercially available software.

Authors:  J E Bennett; J C Wakefield
Journal:  J Pharmacokinet Biopharm       Date:  1996-08

5.  Pharmacokinetic model equations for the one- and two-compartment models with first-order processes in which the absorption and exponential elimination or distribution rate constants are equal.

Authors:  H P Wijnand
Journal:  J Pharmacokinet Biopharm       Date:  1988-02

6.  An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation.

Authors:  J Wakefield; A Racine-Poon
Journal:  Stat Med       Date:  1995 May 15-30       Impact factor: 2.373

7.  The safety of ranitidine bismuth citrate in controlled clinical studies.

Authors:  G A Pipkin; J G Mills; L Kler; J S Dixon; J R Wood
Journal:  Pharmacoepidemiol Drug Saf       Date:  1996-11       Impact factor: 2.890

8.  GR122311X (ranitidine bismuth citrate), a new drug for the treatment of duodenal ulcer.

Authors:  K D Bardhan; C P Dekkers; S K Lam; A Nowak; O B Schaffalitzky de Muckadell; K Schutze; G Tildesley; L Kler; J K Forster; L F Lacey
Journal:  Aliment Pharmacol Ther       Date:  1995-10       Impact factor: 8.171

9.  Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB).

Authors:  L F Lacey; N M Frazer; O N Keene; J T Smith
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  9 in total
  2 in total

1.  Propagation of population pharmacokinetic information using a Bayesian approach: comparison with meta-analysis.

Authors:  Aristides Dokoumetzidis; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

Review 2.  Clinical pharmacokinetics of clarithromycin.

Authors:  K A Rodvold
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.